Beam Therapeutics Inc. (BEAM)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Beam Therapeutics Inc. reported revenue of $139.74M, up 120.0% from the prior year. The company ran a net loss, with a net margin of -57.2%. It held $1.48B in total assets against $242.82M in total liabilities.
Key ratios (FY2025)
-274.6%
Operating margin
-57.2%
Net margin
-6.5%
Return on equity
+120.0%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $139.74M | $63.52M | $377.71M | $60.92M | $51.84M | $24.0K | $18.0K | — |
| Operating Income | -$383.69M | -$415.57M | -$176.49M | -$338.48M | -$392.46M | -$132.76M | -$75.15M | — |
| Net Income | -$79.99M | -$376.74M | -$132.53M | -$289.09M | -$370.64M | -$194.59M | -$78.33M | — |
| EPS (Diluted) | $-0.81 | $-4.58 | $-1.72 | $-4.13 | $-5.77 | $-4.19 | $-14.05 | — |
| Total Assets | $1.48B | $1.10B | $1.46B | $1.34B | $1.47B | $451.68M | $156.10M | — |
| Total Liabilities | $242.82M | $370.28M | $478.38M | $608.24M | $647.72M | $206.12M | $55.15M | — |
| Shareholders' Equity | $1.24B | $733.54M | $981.33M | $733.47M | $826.74M | $245.56M | -$201.10M | -$117.41M |
| Cash & Equivalents | $294.94M | $281.97M | $435.89M | $232.77M | $559.99M | $162.17M | $37.22M | — |
| Operating Cash Flow | -$345.10M | -$347.25M | -$149.19M | $22.53M | -$66.27M | -$95.74M | -$72.00M | — |
| Capital Expenditures | $14.95M | $8.95M | $33.73M | $48.95M | $46.81M | $16.36M | $12.52M | — |
| Shares Outstanding | 101.75M | 83.63M | 81.63M | 71.28M | 68.39M | 57.25M | 7.33M | — |